Results from clinical trials and observational studies suggest that lamivudine plus dolutegravir (3TC+DTG) could be an effective and tolerated option for simplification in human immunodeficiency virus (HIV)-1-positive patients.
Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients / Baldin, Gianmaria; Ciccullo, Arturo; Rusconi, Stefano; Capetti, Amedeo; Sterrantino, Gaetana; Colafigli, Manuela; d'Ettorre, Gabriella; Giacometti, Andrea; Cossu, Maria Vittoria; Borghetti, Alberto; Gennari, William; Mussini, Cristina; Borghi, Vanni; Di Giambenedetto, Simona. - In: INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS. - ISSN 0924-8579. - 54:6(2019), pp. 728-734. [10.1016/j.ijantimicag.2019.09.002]
Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients
Mussini, Cristina;
2019
Abstract
Results from clinical trials and observational studies suggest that lamivudine plus dolutegravir (3TC+DTG) could be an effective and tolerated option for simplification in human immunodeficiency virus (HIV)-1-positive patients.
| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S0924857919302456-main.pdf
Accesso riservato
Tipologia:
VOR - Versione pubblicata dall'editore
Dimensione
704.7 kB
Formato
Adobe PDF
|
704.7 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
